compound glp 1 news 🚨 FDA Cracks Down on Compounded GLP-1s – What's Next for Weight Loss? 🚨 Big in the weight loss world: The FDA is officially shutting down compounding pharmacies producing GLP-1 medications FDA Ban on Compounded GLP-1

Pathological roles of MAPK signaling pathways in human diseases

During a 40-week study 18 , people receiving 1 milligram of Ozempic lost an average of 13 lbs while those receiving a 2-milligram dose lost an average of 15 pounds

(2025) 6:e245586

Lilly is also running two other trials with eloralintide plus tirzepatide, including another mid-stage study in obese and overweight type 2 diabetes patients, with an initial completion date in June 2026, and a Phase I trial in nondiabetic individuals, scheduled to complete in October 2025

A separate analysis published in the journal Addiction examined real-world pharmacy data and found that GLP-1 prescriptions correlated with decreased fills of naltrexone and other AUD medications, suggesting that patients may have been experiencing reduced drinking independently

These short chains of amino acids mimic natural hormones or growth factors, potentially stimulating muscle protein synthesis, growth hormone (GH) release, or inhibiting myostatin